WATS-3D Tissue Sampling for Barrett's Esophagus Detection
What You Need to Know Before You Apply
What is the purpose of this trial?
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How does the WATS-3D treatment for Barrett's Esophagus differ from other treatments?
What data supports the effectiveness of the WATS-3D treatment for Barrett's Esophagus Detection?
Research shows that using WATS-3D along with standard biopsies significantly improves the detection of Barrett's Esophagus and related abnormal cell growth. In a large study, WATS-3D found many more cases of these conditions than biopsies alone, increasing detection rates by over 150% for Barrett's Esophagus and over 240% for abnormal cell growth.12456
Who Is on the Research Team?
Srinadh Komanduri
Principal Investigator
Feinberg School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults over 18 with Barrett's esophagus who've had previous treatment and are under surveillance. They must have shown some healing in a past check-up and be able to give informed consent. Pregnant individuals, prisoners, those with a life expectancy less than a year, severe blood platelet or clotting issues, or an inability to undergo endoscopy safely are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo endoscopic eradication therapy (EET) and subsequent post-EET surveillance with WATS-3D and forceps biopsies
Follow-up
Participants are monitored for recurrence of intestinal metaplasia and dysplasia after treatment
What Are the Treatments Tested in This Trial?
Interventions
- WATS-3D tissue sampling following forceps biopsies
- WATS-3D tissue sampling prior to forceps biopsies
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
Washington University School of Medicine
Collaborator
University of California, Los Angeles
Collaborator
University of Colorado, Denver
Collaborator